Federal officials are wrestling with a decision that could go a long way toward determining the future of the controversial new Alzheimer’s drug, Aduhelm, and whether significant numbers of patients use it.In January, Medicare, the federal health insurance program for people 65 and over, plans to issue a preliminary decision on whether it will cover…
